# Study of Safety and Efficacy in Patients With Malignant Rhabdoid Tumors (MRT) and Neuroblastoma

> **NCT01747876** · PHASE1 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 32 (actual)

## Conditions studied

- Malignant Rhabdoid Tumors (MRT)
- Neuroblastoma

## Interventions

- **DRUG:** LEE011

## Key facts

- **NCT ID:** NCT01747876
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-05-28
- **Primary completion:** 2017-06-29
- **Final completion:** 2017-06-29
- **Target enrollment:** 32 (ACTUAL)
- **Why stopped:** Lack of efficacy caused enrollment to be stopped at the end of dose escalation
- **Last updated:** 2019-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01747876

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01747876, "Study of Safety and Efficacy in Patients With Malignant Rhabdoid Tumors (MRT) and Neuroblastoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01747876. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*